Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 8/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894009 | 0.90 | TRPA1 (0.42) | TRPA1HDAC1HDAC8 | |
| SCHEMBL893983 | 0.86 | TRPA1 (0.46) | TRPA1SCN9ASCN5AKCNH2HDAC8 | |
| SCHEMBL3727154 | 0.85 | TRPA1 (0.56) | TRPA1HDAC1SCN9ASCN5AKCNH2 | |
| SCHEMBL893297 | 0.82 | TRPA1 (0.50) | TRPA1HDAC1SCN9ASCN5AKCNH2 | |
| SCHEMBL893932 | 0.79 | TRPA1 (0.75) | TRPA1 | |
| SCHEMBL894045 | 0.78 | TRPA1 (0.50) | TRPA1HDAC1HDAC8SCN10A | |
| SCHEMBL30838099 | 0.77 | ALDH1A1 (0.50) | HDAC8 | |
| SCHEMBL893916 | 0.77 | TRPA1 (0.55) | TRPA1SCN9A | |
| SCHEMBL893889 | 0.76 | TRPA1 (0.40) | TRPA1 | |
| SCHEMBL3728015 | 0.76 | ALDH1A1 (0.52) | TRPA1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614201-B2 | Heterocyclic amides as modulators of TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-24 | — | — | US | disclosed |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885HDAC1 297/4885SCN9A 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.